⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 2, 2024Open Access

Figure S3 from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin

Anirban Chakraborty Masanori Onda T. O’Shea Junxia Wei Xiufen Liu Tapan K. Bera Ira Pastan

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S3 shows that PBMCs and bispecific antibodies alone are insufficient to kill OVCAR8-Luc cancer cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chakraborty et al. (2024) studied this question.

synapsesocial.com/papers/68e61b6eb6db6435875adc02 https://doi.org/10.1158/1535-7163.26145072.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin2024
2Figure S1 from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin2024
3Supplementary Method S1 from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin2024
4Supplementary Method S1 from A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin2024
5Abstract 2633: A T-cell engager antibody targeting the non-shed site of mesothelin in solid tumors.Original Research · 2026